BG102880A - Cation virosomes as transfer systems for genetic materials - Google Patents
Cation virosomes as transfer systems for genetic materialsInfo
- Publication number
- BG102880A BG102880A BG102880A BG10288098A BG102880A BG 102880 A BG102880 A BG 102880A BG 102880 A BG102880 A BG 102880A BG 10288098 A BG10288098 A BG 10288098A BG 102880 A BG102880 A BG 102880A
- Authority
- BG
- Bulgaria
- Prior art keywords
- virosomes
- cation
- preparation
- transfer systems
- genetic materials
- Prior art date
Links
- 239000000277 virosome Substances 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 150000001768 cations Chemical class 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96107282 | 1996-05-08 | ||
| PCT/EP1997/002268 WO1997041834A1 (en) | 1996-05-08 | 1997-05-04 | Cationic virosomes as transfer system for genetic material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG102880A true BG102880A (en) | 1999-05-31 |
Family
ID=8222763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG102880A BG102880A (en) | 1996-05-08 | 1998-10-29 | Cation virosomes as transfer systems for genetic materials |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6210708B1 (Direct) |
| EP (1) | EP0902682A2 (Direct) |
| JP (1) | JP2000509404A (Direct) |
| KR (1) | KR100536983B1 (Direct) |
| CN (1) | CN1271992C (Direct) |
| AR (1) | AR007054A1 (Direct) |
| AU (1) | AU710170B2 (Direct) |
| BG (1) | BG102880A (Direct) |
| BR (1) | BR9709224A (Direct) |
| CA (1) | CA2253561A1 (Direct) |
| CO (1) | CO4600638A1 (Direct) |
| CZ (1) | CZ299809B6 (Direct) |
| EA (1) | EA003130B1 (Direct) |
| GT (1) | GT199700058A (Direct) |
| HR (1) | HRP970234B1 (Direct) |
| HU (1) | HUP9901790A3 (Direct) |
| ID (1) | ID17934A (Direct) |
| NO (1) | NO327726B1 (Direct) |
| NZ (1) | NZ332666A (Direct) |
| OA (1) | OA10916A (Direct) |
| PA (1) | PA8429201A1 (Direct) |
| PE (1) | PE65198A1 (Direct) |
| PL (1) | PL199201B1 (Direct) |
| SK (1) | SK152698A3 (Direct) |
| SV (1) | SV1997000032A (Direct) |
| TN (1) | TNSN97080A1 (Direct) |
| WO (1) | WO1997041834A1 (Direct) |
| ZA (1) | ZA973885B (Direct) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030113347A1 (en) * | 1991-05-08 | 2003-06-19 | Schweiz. Serum- & Impfinstitut Bern | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them |
| EP1011735A1 (en) * | 1997-09-08 | 2000-06-28 | Promega Corporation | METHOD OF $i(IN VIVO) TRANSFORMATION UTILIZING LIPID VEHICLES |
| SE513149C2 (sv) * | 1997-12-05 | 2000-07-17 | Katarina Edwards | Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna |
| GB9813100D0 (en) * | 1998-06-18 | 1998-08-19 | Secr Defence | Method of forming liposomes |
| CA2388053A1 (en) * | 1999-10-08 | 2001-04-19 | Nika Health Products Limited | Cationic dosper virosomes |
| WO2001044023A1 (de) * | 1999-12-17 | 2001-06-21 | Duerschinger Guenter | Induktiv aktivierbare zündkapsel für insassen-rückhaltesysteme und prüfschaltung für diese zündkapsel |
| US20030139361A1 (en) * | 2000-01-21 | 2003-07-24 | Kazuhiro Yuda | Drug for gene therapy |
| JP2004536607A (ja) * | 2001-07-23 | 2004-12-09 | オニックス ファーマシューティカルズ，インコーポレイティド | 標的化されたヒト癌細胞において選択的に複製するウイルス変異体 |
| KR100411234B1 (ko) * | 2001-08-14 | 2003-12-18 | 한국과학기술원 | 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법 |
| WO2003038103A1 (en) * | 2001-10-29 | 2003-05-08 | Atso Raasmaja | Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers |
| US20040028687A1 (en) * | 2002-01-15 | 2004-02-12 | Waelti Ernst Rudolf | Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues |
| US20040176283A1 (en) * | 2002-04-01 | 2004-09-09 | Robinson John A. | Methods and compositions for the design of synthetic vaccines |
| EA008497B1 (ru) * | 2002-11-21 | 2007-06-29 | Певион Биотех Лтд. | Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая |
| CA2543257C (en) | 2003-10-24 | 2013-12-31 | Gencia Corporation | Methods and compositions for delivering polynucleotides |
| US8062891B2 (en) | 2003-10-24 | 2011-11-22 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to plants |
| US20090208478A1 (en) * | 2003-10-24 | 2009-08-20 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| US8507277B2 (en) | 2003-10-24 | 2013-08-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides |
| US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
| DE102004057303A1 (de) * | 2004-11-26 | 2006-06-01 | Merck Patent Gmbh | Stabile Kristallmodifikationen von DOTAP Chlorid |
| US20070172520A1 (en) * | 2005-11-18 | 2007-07-26 | University Of South Florida | Immunotargeting of Nonionic Surfactant Vesicles |
| EP2064229B1 (en) * | 2006-09-15 | 2015-08-12 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
| KR101242113B1 (ko) * | 2010-10-22 | 2013-03-19 | 고마바이오텍(주) | 유전자 전달용 양이온성 센다이 ｆ／ｈｎ 바이로좀 복합체 |
| WO2013032643A2 (en) * | 2011-08-31 | 2013-03-07 | Dicerna Pharmaceuticals, Inc. | Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells |
| US20140335117A1 (en) * | 2011-10-07 | 2014-11-13 | Skau Aps | Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses |
| MX383392B (es) | 2016-09-27 | 2025-03-13 | Camurus Ab | Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta). |
| CN109055432B (zh) * | 2018-08-16 | 2020-10-13 | 南京科佰生物科技有限公司 | 慢病毒感染试剂及其制备方法与应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| PL296382A1 (en) * | 1991-02-02 | 1993-11-02 | Nika Health Products Ltd Li Li | Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system |
| AU655823B2 (en) * | 1991-05-08 | 1995-01-12 | Crucell Switzerland Ag | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them |
| AU3614493A (en) | 1992-02-04 | 1993-09-01 | Chiron Corporation | Non-toxic lipid vaccine formulations |
| US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
| US5578475A (en) * | 1993-07-12 | 1996-11-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
| EP0762870B1 (en) * | 1994-05-31 | 2002-09-11 | INEX Pharmaceutical Corp. | Virosome-mediated intracellular delivery of therapeutic agents |
| FR2726764B1 (fr) | 1994-11-14 | 1997-01-31 | Pasteur Merieux Serums Vacc | Adjuvant pour composition vaccinale |
-
1997
- 1997-05-04 AU AU27766/97A patent/AU710170B2/en not_active Ceased
- 1997-05-04 CZ CZ0361498A patent/CZ299809B6/cs not_active IP Right Cessation
- 1997-05-04 CA CA002253561A patent/CA2253561A1/en not_active Abandoned
- 1997-05-04 EP EP97921852A patent/EP0902682A2/en not_active Withdrawn
- 1997-05-04 HU HU9901790A patent/HUP9901790A3/hu unknown
- 1997-05-04 JP JP9539526A patent/JP2000509404A/ja active Pending
- 1997-05-04 CN CNB971962324A patent/CN1271992C/zh not_active Expired - Fee Related
- 1997-05-04 NZ NZ332666A patent/NZ332666A/xx unknown
- 1997-05-04 WO PCT/EP1997/002268 patent/WO1997041834A1/en not_active Ceased
- 1997-05-04 KR KR1019980708906A patent/KR100536983B1/ko not_active Expired - Fee Related
- 1997-05-04 BR BR9709224A patent/BR9709224A/pt unknown
- 1997-05-04 EA EA199800992A patent/EA003130B1/ru not_active IP Right Cessation
- 1997-05-04 SK SK1526-98A patent/SK152698A3/sk unknown
- 1997-05-04 PL PL329853A patent/PL199201B1/pl not_active IP Right Cessation
- 1997-05-06 ZA ZA973885A patent/ZA973885B/xx unknown
- 1997-05-07 HR HR970234A patent/HRP970234B1/xx not_active IP Right Cessation
- 1997-05-07 TN TNTNSN97080A patent/TNSN97080A1/fr unknown
- 1997-05-07 SV SV1997000032A patent/SV1997000032A/es unknown
- 1997-05-07 CO CO97024481A patent/CO4600638A1/es unknown
- 1997-05-07 PE PE1997000354A patent/PE65198A1/es not_active Application Discontinuation
- 1997-05-07 GT GT199700058A patent/GT199700058A/es unknown
- 1997-05-08 AR ARP970101917A patent/AR007054A1/es not_active Application Discontinuation
- 1997-05-08 PA PA19978429201A patent/PA8429201A1/es unknown
- 1997-05-09 ID IDP971533A patent/ID17934A/id unknown
-
1998
- 1998-10-29 BG BG102880A patent/BG102880A/xx unknown
- 1998-11-04 NO NO19985137A patent/NO327726B1/no not_active IP Right Cessation
- 1998-11-06 OA OA9800214A patent/OA10916A/en unknown
-
1999
- 1999-10-08 US US09/414,872 patent/US6210708B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG102880A (en) | Cation virosomes as transfer systems for genetic materials | |
| Seyedin et al. | Purification and characterization of two cartilage-inducing factors from bovine demineralized bone. | |
| Butler | The nature and significance of osteopontin | |
| Kasugai et al. | Differential regulation of the 55 and 44 kDa forms of secreted phosphoprotein 1 (SPP-1, osteopontin) in normal and transformed rat bone cells by osteotropic hormones, growth factors and a tumor promoter | |
| Ihle et al. | Phenotypic characteristics of cell lines requiring interleukin 3 for growth. | |
| Nagata et al. | Biosynthesis of bone proteins [SPP-1 (secreted phosphoprotein-1, osteopontin), BSP (bone sialoprotein) and SPARC (osteonectin)] in association with mineralized-tissue formation by fetal-rat calvarial cells in culture | |
| Brunner et al. | Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells | |
| Wang et al. | Purification and characterization of other distinct bone-inducing factors. | |
| CA2457632C (en) | Identification and isolation of somatic stem cells and uses thereof | |
| Guy et al. | Coordinated action of IgE and a B-cell-stimulatory factor on the CD23 receptor molecule up-regulates B-lymphocyte growth. | |
| Stadie et al. | Studies on the order and site specificity of GalNAc transfer to MUC1 tandem repeats by UDP‐GalNAc: polypeptide N‐acetylgalactosaminyltransferase from milk or mammary carcinoma cells | |
| ZA953629B (en) | Soluble polypeptidic fragments of lag-3 protein method of production thereof therapeutic composition anti-idiotype antibodies | |
| MX9702714A (es) | Produccion de peptidos en plantas como fusiones de proteinas con revestimiento viral. | |
| AU2002355970A1 (en) | Identification and isolation of somatic stem cells and uses thereof | |
| AU3509995A (en) | Overexpression of mammalian and viral proteins | |
| Schwartz-Albiez et al. | Differential expression of annexins I and II in normal and malignant human mammary epithelial cells | |
| WO2000043499A3 (en) | ANTI-TRANSFORMING GROWTH FACTOR BETA (TGF-β) TREATED STEM CELL COMPOSITION AND METHOD | |
| GB9722320D0 (en) | Human cell cycle checkpoint proteins | |
| Okamura et al. | Localization of a maturation-dependent epididymal sperm surface antigen recognized by a monoclonal antibody raised against a 135-kilodalton protein in porcine epididymal fluid | |
| Clark et al. | Characterization of murine pregnancy decidua transforming growth factor b. I. Transforming growth factor b2-like molecules of unusual molecular size released in bioactive form | |
| DE3751319D1 (de) | VERWENDUNG UND ZUSAMMENSETZUNG ZUR VERBESSERUNG DES "TARGETING" VON ANTIKöRPERN, ANTIKöRPERTEILEN, SOWIE KONJUGATE DERSELBEN. | |
| Bocchini et al. | Glial fibrillary acidic protein and its encoding mRNA exhibit mosaic expression in a glioblastoma multiform cell line of clonal origin | |
| Chomette et al. | Basaloid carcinoma of salivary glands, a variety of undifferentiated adenocarcinoma. Immunohistochemical study of intermediate filament proteins in 24 cases | |
| Mizuno et al. | The osteoblastic MC3T3-E1 cells synthesized C-terminal propeptide of type I collagen, which promoted cell-attachment of osteoblasts | |
| Remold-O'Donnell | Macrophage component gp160, a major trypsin-sensitive surface glycoprotein. |